Approval · Notice of Compliance 17276 · 2015
ABILIFY MAINTENA: Notice of Compliance 17276
Issued September 16, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17276
- Date
- September 16, 2015
- Company
- Otsuka Pharmaceutical Co LtdChiyoda-Ku Tokyo, Japan
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Expansion of indication to include treatment of acute episodes of schizophrenia
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ABILIFY MAINTENA | Not yet assigned | — |
Medicinal ingredients
- ARIPIPRAZOLE 300 MG per VIAL
- ARIPIPRAZOLE 400 MG per VIAL
- ARIPIPRAZOLE 300 MG per SYR
- ARIPIPRAZOLE 400 MG per SYR